A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

Inclusion Criteria: * Participants included in the TAU from 26 February 2015 * Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib * For alive participants: participants who have been informed verbally and in writing about this study who do not object to their data being electronically processed or subjected to data quality control * For participants who died before the inclusion period: participants who did not express their opposition when they were alive Exclusion Criteria: \- Alive participants unable to give informed consent